The virus shredder: A Princeton spinout advised by a high-profile VC launches a Cas13 viral defense system
Cameron Myhrvold is one of those young scientists who’s been earning double takes for the cutting-edge research work he’s been doing, even before joining Princeton in 2020. But after getting his PhD in systems biology at Harvard seven years ago, he eventually turned to Cas13, a CRISPR effector — Cas9 is the famous one used on DNA — that is targeted at single-stranded RNA instead of double-stranded DNA.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.